Adage Capital Partners Gp, L.L.C. Eagle Pharmaceuticals, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$15.21 - $22.88 $1.52 Million - $2.29 Million	100,000 Added 25.0%	500,000 $7.89 Million
Q4 2022 Feb 14, 2023	BUY	$24.98 - $39.77 $3.75 Million - $5.97 Million	150,000 Added 60.0%	400,000 $11.7 Million
Q2 2022 Aug 15, 2022	BUY	$41.26 - $51.35 $10.3 Million - $12.8 Million	250,000 New	250,000 $11.1 Million
Q3 2018 Nov 14, 2018	SELL	$66.65 - $83.86 $3.33 Million - $4.19 Million	-50,000 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$51.25 - $76.62 $2.56 Million - $3.83 Million	50,000 New	50,000 $3.78 Million

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.